277 related articles for article (PubMed ID: 37914894)
21. Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies.
Aygören-Pürsün E; Magerl M; Maetzel A; Maurer M
Orphanet J Rare Dis; 2018 May; 13(1):73. PubMed ID: 29728119
[TBL] [Abstract][Full Text] [Related]
22. [Pharmacological and clinical study results of Berotralstat Hydrochloride for long-term prophylactic treatment of hereditary angioedema].
Orui S; Nozue H; Kobayashi S; Fujioka M; Maekawa Y
Nihon Yakurigaku Zasshi; 2021; 156(6):382-390. PubMed ID: 34719573
[TBL] [Abstract][Full Text] [Related]
23. Hereditary Angioedema with Normal C1 Inhibitor: Update on Evaluation and Treatment.
Magerl M; Germenis AE; Maas C; Maurer M
Immunol Allergy Clin North Am; 2017 Aug; 37(3):571-584. PubMed ID: 28687110
[TBL] [Abstract][Full Text] [Related]
24. C1 Inhibitor Activity and Angioedema Attacks in Patients with Hereditary Angioedema.
Kaplan AP; Pawaskar D; Chiao J
J Allergy Clin Immunol Pract; 2020 Mar; 8(3):892-900. PubMed ID: 31655295
[TBL] [Abstract][Full Text] [Related]
25. Treatment of hereditary angioedema-single or multiple pathways to the rescue.
Valerieva A; Longhurst HJ
Front Allergy; 2022; 3():952233. PubMed ID: 36172291
[TBL] [Abstract][Full Text] [Related]
26. Recombinant human C1 esterase inhibitor in the management of hereditary angioedema.
Riedl M
Clin Drug Investig; 2015 Jul; 35(7):407-17. PubMed ID: 26091744
[TBL] [Abstract][Full Text] [Related]
27. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial.
Zuraw B; Lumry WR; Johnston DT; Aygören-Pürsün E; Banerji A; Bernstein JA; Christiansen SC; Jacobs JS; Sitz KV; Gower RG; Gagnon R; Wedner HJ; Kinaciyan T; Hakl R; Hanzlíková J; Anderson JT; McNeil DL; Fritz SB; Yang WH; Tachdjian R; Busse PJ; Craig TJ; Li HH; Farkas H; Best JM; Clemons D; Cornpropst M; Dobo SM; Iocca HA; Kargl D; Nagy E; Murray SC; Collis P; Sheridan WP; Maurer M; Riedl MA
J Allergy Clin Immunol; 2021 Jul; 148(1):164-172.e9. PubMed ID: 33098856
[TBL] [Abstract][Full Text] [Related]
28. [Acquired C1 esterase inhibitor deficiency via bradykinin-mediated angioedema: Four cases].
Jacquin-Porretaz C; Castelain F; Daguindau E; Seilles E; Nardin C; Aubin F; Pelletier F
Ann Dermatol Venereol; 2018 Oct; 145(10):598-602. PubMed ID: 29673745
[TBL] [Abstract][Full Text] [Related]
29. Angioedema due to acquired C1-inhibitor deficiency: spectrum and treatment with C1-inhibitor concentrate.
Bork K; Staubach-Renz P; Hardt J
Orphanet J Rare Dis; 2019 Mar; 14(1):65. PubMed ID: 30866985
[TBL] [Abstract][Full Text] [Related]
30. Recombinant human C1 esterase inhibitor for the treatment of hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE).
Sabharwal G; Craig T
Expert Rev Clin Immunol; 2015 Mar; 11(3):319-27. PubMed ID: 25669442
[TBL] [Abstract][Full Text] [Related]
31. Chapter 22: Hereditary and acquired angioedema.
Georgy MS; Pongracic JA
Allergy Asthma Proc; 2012; 33 Suppl 1():73-76. PubMed ID: 22794695
[TBL] [Abstract][Full Text] [Related]
32. A Decade of Change: Recent Developments in Pharmacotherapy of Hereditary Angioedema (HAE).
Bork K
Clin Rev Allergy Immunol; 2016 Oct; 51(2):183-92. PubMed ID: 27207174
[TBL] [Abstract][Full Text] [Related]
33. Recombinant human C1 esterase inhibitor (Conestat alfa) for prophylaxis to prevent attacks in adult and adolescent patients with hereditary angioedema.
Valerieva A; Caccia S; Cicardi M
Expert Rev Clin Immunol; 2018 Sep; 14(9):707-718. PubMed ID: 30021471
[TBL] [Abstract][Full Text] [Related]
34. Long-term safety and effectiveness of berotralstat for hereditary angioedema: The open-label APeX-S study.
Farkas H; Stobiecki M; Peter J; Kinaciyan T; Maurer M; Aygören-Pürsün E; Kiani-Alikhan S; Wu A; Reshef A; Bygum A; Fain O; Hagin D; Huissoon A; Jeseňák M; Lindsay K; Panovska VG; Steiner UC; Zubrinich C; Best JM; Cornpropst M; Dix D; Dobo SM; Iocca HA; Desai B; Murray SC; Nagy E; Sheridan WP
Clin Transl Allergy; 2021 Jun; 11(4):e12035. PubMed ID: 34161665
[TBL] [Abstract][Full Text] [Related]
35. A follow-up survey of patients with acquired angioedema due to C1-inhibitor deficiency.
Pólai Z; Balla Z; Andrási N; Kőhalmi KV; Temesszentandrási G; Benedek S; Varga L; Farkas H
J Intern Med; 2021 Apr; 289(4):547-558. PubMed ID: 33215769
[TBL] [Abstract][Full Text] [Related]
36. Clinical Characteristics and Safety of Plasma-Derived C1-Inhibitor Therapy in Children and Adolescents with Hereditary Angioedema-A Long-Term Survey.
Farkas H; Kőhalmi KV; Visy B; Veszeli N; Varga L
J Allergy Clin Immunol Pract; 2020; 8(7):2379-2383. PubMed ID: 32198128
[TBL] [Abstract][Full Text] [Related]
37. Orladeyo (Berotralstat): A Novel Oral Therapy for the Prevention of Hereditary Angioedema.
Powell J; Piszczatoski C; Rubido E
Ann Pharmacother; 2022 Apr; 56(4):488-493. PubMed ID: 34282650
[TBL] [Abstract][Full Text] [Related]
38. Hereditary and acquired C1-inhibitor-dependent angioedema: from pathophysiology to treatment.
Zeerleder S; Levi M
Ann Med; 2016; 48(4):256-67. PubMed ID: 27018196
[TBL] [Abstract][Full Text] [Related]
39. Current options for prophylactic treatment of hereditary angioedema in the United States: patient-based considerations.
Gower RG; Lumry WR; Davis-Lorton MA; Johnston DT; Busse PJ
Allergy Asthma Proc; 2012; 33(3):235-40. PubMed ID: 22584192
[TBL] [Abstract][Full Text] [Related]
40. Acquired Angioedema due to C1-Inhibitor Deficiency: A Challenging Condition.
Valle SOR; Alonso MLO; Dortas Junior SD; Goudouris ES; de Carvalho ALRB; Capelo AV; Mansour E; Bernardes AF; Leite LFB; Giavina-Bianchi P; Aun MV; Ferriani MPL; Arruda LK; Grumach AS
Int Arch Allergy Immunol; 2022; 183(5):572-577. PubMed ID: 35325890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
